1. Györffy B, Kovács Z, Gulyássy P, Simor A, Völgyi K, Orbán G, et al. Brain protein expression changes in WAG/Rij rats, a genetic rat model of absence epilepsy after peripheral lipopolysaccharide treatment. Brain Behav Immun 2014; 35: 86-95.

2. Bernstein GA, Carroll ME, Thuras PD, Cosgrove KP, Roth ME. Caffeine dependence in teenagers. Drug Alcohol Depend 2002; 66(1): 1-6.

3. El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, et al. Adenosine A2A receptor antagonists are potential anti‌dep‌re‌ssants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 2001; 134(1): 68-77.

4. Luszczki JJ, Zuchora M, Sawicka KM, Kozi‌ńska J, Czuczwar SJ. Acute exposure to caffeine dec‌reases the anticonvulsant action of etho‌su‌ximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. Pharmacol Rep 2006; 58(5): 652-9.

5. Bonilha L, Li LM. Heavy coffee drinking and epilepsy. Seizure 2004; 13(4): 284-5.

6. Löscher W. Preclinical assessment of proco‌n‌vulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 2009; 610(1-3): 1-11.

7. Chrościńska-Krawczyk M, Jargiełło-Baszak M, Wałek M, Tylus B, Czuczwar SJ. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol Rep 2011; 63(1): 12-8.

8. Calabrò RS, Italiano D, Gervasi G, Bramanti P. Single tonic–clonic seizure after energy drink ab‌use. Epilepsy Behav 2012; 23(3): 384-5.

9. Bankstahl M, Bankstahl JP, Bloms-Funke P, Löscher W. Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models. Neurotoxicology 2012; 33(1): 127-37.

10. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010; 316(8): 1284-8.

11. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. Evidence for the invol‌ve‌ment of the adenosine A(2A) receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine. Neuropharmacology 2008; 55(1): 35-40.

12. Boison D. Methylxanthines, seizures, and excito‌toxicity. Handb Exp Pharmacol 2011; (200): 251-66.

13. Etherington AV, Frenguelli BG. Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent man‌ner. Eur J Neurosci 2004; 19(9): 2539-50.

14. Zandieh A, Maleki F, Hajimirzabeigi A, Zan‌dieh B, Khalilzadeh O, Dehpour AR. Anti‌con‌vulsant effect of celecoxib on pentylenetetrazole-induced convulsion: Modulation by NO pathway. Acta Neurobiol Exp 2010; 70(4): 390-7.

15. Akula KK, Dhir A, Kulkarni S. Nitric oxide signaling pathway in the anti-convulsant effect of adenosine against pentylenetetrazol-induced seizure threshold in mice. Eur J Pharmacol 2008; 587(1-3): 129-34.

16. Bruce C, Yates DH, Thomas PS. Caffeine decre‌ases exhaled nitric oxide. Thorax 2002; 57(4): 361-3.

17. Ardais A, Borges MF, Rocha AS, Sallaberry C, Cunha R, Porciúncula L. Caffeine triggers behav‌ioral and neurochemical alterations in adolescent rats. Neuroscience 2014; 270: 27-39.

18. Heydari A, Davoudi S. The effect of sertraline and 8-OH-DPAT on the PTZ_induced seizure thre‌shold: Role of the nitrergic system. Seizure 2017; 45: 119-24.

19. Huang RQ, Bell-Horner CL, Dibas MI, Covey DF, Drewe JA, Dillon GH. Pentylenetetrazole-induced inhibition of recombinant gamma-amino‌butyric acid type A (GABA(A)) receptors: mecha‌nism and site of action. J Pharmacol Exp Ther 2001; 298(3): 986-95.

20. Porciúncula LO, Sallaberry C, Mioranzza S, Botton PH, Rosemberg DB. The Janus face of caffeine. Neurochem Int 2013; 63(6): 594-609.

21. Chrościńska-Krawczyk M, Jargiełło-Baszak M, Andres-Mach M, Łuszczki JJ, Czuczwar SJ. Inf‌l‌uence of caffeine on the protective activity of gabapentin and topiramate in a mouse model of generalized tonic-clonic seizures. Pharmacol Rep 2016; 68(4): 680-5.

22. Germé K, Faure JB, Koning E, Nehlig A. Effect of caffeine and adenosine receptor ligands on the expression of spike-and-wave discharges in Gen‌etic Absence Epilepsy Rats from Strasbourg (GAERS). Epilepsy Res 2015; 110: 105-14.

23. Matovu D, Alele PE. Seizure vulnerability and anxiety responses following chronic co-admini‌st‌ration and acute withdrawal of caffeine and ethanol in a rat model. J Basic Clin Physiol Pharmacol 2018; 26; 29(1): 1-10.

24. Mareš P. A1 not A2A adenosine receptors play a role in cortical epileptic afterdischarges in imma‌ture rats. J Neural Transm 2014; 121(11): 1329-36.

25. Cunha RA, Agostinho PM. Chronic caffeine cons‌u‌mption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis 2010; 20(1): S95-116.

26. Tavares C, Sakata RK. Caffeine in the treat‌ment of pain. Rev Bras Anestesiol 2012; 62(3): 387-401.

27. Rigoulot MA, Leroy C, Koning E, Ferrandon A, Nehlig A. Prolonged low-dose caffeine exposure protects against hippocampal damage but not against the occurrence of epilepsy in the lithium-pilocarpine model in the rat. Epilepsia 2003; 44(4): 529-35.

28. Riazi K, Roshanpour M, Rafiei Tabatabaei N, Homayoun H, Ebrahimi F, Dehpour AR. The proconvulsant effect of sildenafil in mice: role of nitric oxide–cGMP pathway. Br J Pharmacol 2006; 147(8): 935-43.

29. Vincent SR. Nitric oxide neurons and neurotra‌nsmission. Prog Neurobiol 2010; 90(2): 246-55.